Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced
Sanofi drug to treat 'smoker's lung' clears trial, says report
Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate France's Sanofi to acquire US-based Provention Bio for $2.9 bn
With the acquisition, Sanofi intends to acquire full ownership of an innovative treatment for the delay of stage 3 type 1 diabetes Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice to Shareholders of the Company published on 1st March 2023 in the following newspapers: 1. Business Standard (English) 2. Sakal (Marathi)
Hold Sanofi India; target of Rs 6270: ICICI Direct
ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6270 in its research report dated February 27, 2023. Sanofi India Ltd - 500674 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24(A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, The Secretarial Compliance Report for the year ended 31st December 2022, issued by Ms. Deepti Joshi, Practicing Company Secretary of M/s. MMJB & Associates LLP Company Secretaries. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The transcript of the Investors / Analysts Call held on 24th February 2023